Nitroglycerin (IV)

Nitroglycerin (Iv)

Form: Intravenous (IV) infusion solution

Strength: 5 mg/mL in 5 mL or 10 mL vials

Reference Brands: Tridil®(US); Perlinganit®(EU)

Category: Critical Care

Nitroglycerin (IV) is a critical vasodilator used in acute angina, heart failure, and hypertensive emergencies. Administered via continuous IV infusion, it is typically available in strengths like 5 mg/mL and premixed bags of 25 mg or 50 mg in 250 mL solutions. Leading brands include Tridil® in the US and Perlinganit® in the EU, with generics available from global manufacturers like Baxter and Fresenius. Pharma B2B platforms support bulk procurement of Nitroglycerin IV for hospitals and ICUs, offering regulatory-compliant, GMP-grade products with assured cold chain logistics and timely delivery across international mar

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (Iv)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more